click enter text
ex-u opportun substanti under-
commerci histori numer cancer drug consist show
ex-u sale often peak level greater us
word ratio ex-us-to-u sale commonli hit higher
despit case anti-pdx therapi we/consensu current model
ex-us-to-u sale ratio ever reach even distant out-year
preced therefor suggest peak ex-u anti-pdx sale may
report examin hypothet upsid gross ex-u
forecast sale ratio ex-us-to-u eventu rise
four categori leader mrk keytruda bmi opdivo azn
imfinzi rog tecentriq
impact ep dramat depend compani addit
sale would gener high increment profit uplift could
increment keytruda sale lift ep
increment opdivo sale lift ep
azn increment imfinzi sale lift ep
increment tecentriq sale lift
rough model exercis meant bracket upsid potenti
chang estim time support evid
compel warrant consider also
support view investor seek exposur
import class drug
rate azn outperform rate market-
perform inform compani cover see
 april issu monthli controversi report
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
anti-pdx class drug paradigm shift term cancer patient manag
categori support unpreced level invest industri analyst forecast
drug alreadi sit impress high level still addit sourc upsid contempl
three commonli cite includ move anti-pdx therapi upstream manag cancer
metastat adjuv set figur combin either exist cancer
medicin new one develop may make anti-pdx even effect potenti
under-model ex-u anti-pdx opportun
report focus exclus third item ex-u anti-pdx opportun
preced consist show ex-u cancer drug sale eventu outpac us sale analysi
commerci histori prior cancer drug consist show sale ex-u market often peak level
greater us word ratio ex-us-to-u sale commonli hit
least
simpli put oncolog patient outsid us us remain true
restrict comparison treat patient develop nation like franc germani itali spain unit
kingdom eu japan includ high-incom countri benelux nordic canada australia
emerg market countri like brazil china even appli afford filter amplifi
ex-u advantag
exhibit show treat cancer patient major geographi tumor type reveal much greater patient
exhibit treat patient tumor type geographi
iv ajcc stage iv advanc appli ovarian cancer mean cancer spread outsid ovari correspond ajcc stage ii
china popul market access afford cut
page
ratio exus/u us iv tnbc neckiv egfrmt advanc stage annual treat patient
exhibit chart histor ex-u us sale individu cancer product express ratio ex-u sales-
to-u sale sale product often hit ratio greater peak patent expir
gener entri even though price ex-u market almost alway lower us price hold
true small molecul alimta larg molecul avastin oncolog drug
preced product limit sampl set larger oncolog drug acknowledg clinic benefit
repres ed standard care across major market drug widest access
fewest restrict use attribut similar anti-pdx categori enjoy exclud
drug histor reason launch later us eloxatin exampl late us
launch drug materi proport non-oncolog sale rituxan get use mani
condit on- off-label
exhibit ratio ex-us-to-u sale larg matur oncolog drug
product reach loe major market data seri truncat year immedi prior loe
sale ratio calcul world-wide sale report year omit
page
current analyst forecast intern sale therapi ever reach
higher level despit preced case anti-pdx therapi we/consensu model ex-us-to-
us sale ratio even reach even distant out-year
exhibit show consensu ex-us-to-u sale ratio averag across four lead anti-pdx
product compar red line repres averag preced product shown
note composit ratio weight averag us ex-u sale keytruda opdivo tecentriq imfinzi actual ratio product
present exhibit x-i
under-model two possibl reason think
first reason may simpli come overal lack appreci analyst
commun matur cancer drug histor sold aggreg across ex-u
geographi product tail end lifecycl focus much analyst newer
product still develop earli phase launch
page
second reason forecast influenc recent trend case anti-pdx
us sale current outpac intern market uncommon
fact happen cancer drug preced analyz howev
point matur cycl rel contribut flip ex-u sale end surpass
us us almost alway see faster uptak regulatori approv market
access/reimburs fall place quickli
time differ probabl reason think time differ mean
anti-pdx therapi dont follow sale preced set oncolog drug view
one differ consid howev number already-approv anti-pdx product market
vs preced drug like herceptin true monopoli approv product class
principl greater number competitor could lead price competit someth investor
clearli alreadi wonder howev maintain like occur anti-pdx base
belief four lead product larg shut later entrant virtu first-mov statu
releg other nich indic often narrow label mechan would
ordinarili support robust price competit name label pariti across mani product similar point
time lack even among four lead therapi dynam alreadi play
keytruda opdivo much stronger posit much broader usag given greater number
indic approv compar imfinzi tecentriq
say wont price competit select market us aggreg like
manag wont influenc ex-us-to-u sale ratio much china one market price
competit alreadi emerg two domest produc product appear sell discount vs
brand like keytruda preced analyz emerg market compon sale
much factor anyway em contribut w/w sale low moment
anti-pdx therapi em contribut much futur anti-pdx categori would actual serv
strengthen ex-us-to-u sale ratio
model exercis happen revenu ep anti-pdx follow suit exercis
examin sale ep uplift four io leader would enjoy histori suggest ex-u sale
come exceed us meant bracket approxim term upsid could
use current forecast start point
slowli rais ex-u sale eventu reach us sale key assumpt us forecast
accur dont let ratio exceed howev
estim oper incom gain increment sale oper margin increment
sale high gener within nearli fix cost base
tax gain compani corpor tax rate
rel easi understand peak sale could eventu favor intern market
difficult know exactli line may cross mean intern overtak us preced
suggest occur time-frame plu minu year approxim time-frame
incorpor analysi dont attempt tie ramp specif futur event addit
on-going trial read
page
addit import point worth appreci categori first keytruda opdivo
launch ago face patent expiri around late almost
shown exhibit especi out-year theoret upsid could
meaning azn modest
merck keytruda exhibit begin rais ex-us-to-u sale ratio start goe
current model hypothet reach current model
take account royalti pay lessen time current pay royalti
bmy/ono w/w keytruda sale drop period disappear
incorpor chang
view increment keytruda sale lead ep boost
view increment keytruda sale lead ep boost
ep cagr compound-annual-growth-rate rise compound-annual-growth-rate rise
page
current us us suggest us ratio keytrudawolf revenu use preced wolf pre-tax margin increment tax incom increment increas
bristol-my squibb opdivo exhibit begin rais ex-us-to-u sale ratio start
goe current model hypothet reach current
model analysi use pro-forma bmi celg estim
incorpor chang
view increment opdivo sale lead ep boost
view increment opdivo sale lead ep boost
ep cagr compound-annual-growth-rate rise compound-annual-growth-rate rise
page
current us us suggest us ratio opdivowolf revenu use preced wolf pre-tax margin increment tax incom increment outstand pro-forma ep pro-forma increas
astrazeneca imfinzi exhibit begin rais ex-us-to-u sale ratio start goe
current model hypothet reach current model
consensu around
incorpor chang
view increment imfinzi sale lead ep boost
view increment imfinzi sale lead ep boost
ep cagr compound-annual-growth-rate rise compound-annual-growth-rate rise
royalti oblig assum
page
current us us suggest us ratio imfinziwolf revenu use preced wolf pre-tax margin increment tax incom increment increas
roch tecentriq exhibit begin rais ex-us-to-u sale ratio start goe
current model hypothet reach current model rog
larg revenu base dampen impact increment sale
incorpor chang
view increment tecentriq sale chf lead ep boost
view increment tecentriq sale lead ep boost
ep cagr compound-annual-growth-rate rise compound-annual-growth-rate rise
page
current us revenueschf revenueschf us revenueschf market indic onlyconsensu revenueschf suggest us ratio tecentriqwolf revenu use preced ratio chf wolf revenueschf chf pre-tax margin increment tax incom increment epschf epschf epschf increas
exhibit analysi ex-u us sale ratio sinc launch year
nc calcul ww sale pink box repres first year ex-u sale exceed us sale outlin box indic year first
loss exclus major market
loe loss exclus europ us peri-lo loss exclus one major market matur brand product late life-cycle immatur
brand product earli life-cycle addit indic launch on-going clinic develop
page
